| Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3 … YJ Bang, E Van Cutsem, A Feyereislova, HC Chung, L Shen, A Sawaki, ... The Lancet 376 (9742), 687-697, 2010 | 8208 | 2010 |
| Anaplastic lymphoma kinase inhibition in non–small-cell lung cancer EL Kwak, YJ Bang, DR Camidge, AT Shaw, B Solomon, RG Maki, SHI Ou, ... New England Journal of Medicine 363 (18), 1693-1703, 2010 | 5492 | 2010 |
| Sunitinib malate for the treatment of pancreatic neuroendocrine tumors E Raymond, L Dahan, JL Raoul, YJ Bang, I Borbath, C Lombard-Bohas, ... New England Journal of Medicine 364 (6), 501-513, 2011 | 3037 | 2011 |
| Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair–deficient cancer: results from the phase II KEYNOTE-158 study A Marabelle, DT Le, PA Ascierto, AM Di Giacomo, A De Jesus-Acosta, ... Journal of Clinical Oncology 38 (1), 1-10, 2020 | 2504 | 2020 |
| Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer AT Shaw, SHI Ou, YJ Bang, DR Camidge, BJ Solomon, R Salgia, GJ Riely, ... New England Journal of Medicine 371 (21), 1963-1971, 2014 | 2219 | 2014 |
| Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial YJ Bang, YW Kim, HK Yang, HC Chung, YK Park, KH Lee, KW Lee, ... The Lancet 379 (9813), 315-321, 2012 | 1967 | 2012 |
| Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort … A Marabelle, M Fakih, J Lopez, M Shah, R Shapira-Frommer, ... The Lancet Oncology 21 (10), 1353-1365, 2020 | 1897 | 2020 |
| Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial CS Fuchs, T Doi, RW Jang, K Muro, T Satoh, M Machado, W Sun, SI Jalal, ... JAMA oncology 4 (5), e180013-e180013, 2018 | 1797 | 2018 |
| Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study DR Camidge, YJ Bang, EL Kwak, AJ Iafrate, M Varella-Garcia, SB Fox, ... The lancet oncology 13 (10), 1011-1019, 2012 | 1555 | 2012 |
| KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors DS Hong, MG Fakih, JH Strickler, J Desai, GA Durm, GI Shapiro, ... New England Journal of Medicine 383 (13), 1207-1217, 2020 | 1474 | 2020 |
| Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial K Shitara, M Özgüroğlu, YJ Bang, M Di Bartolomeo, M Mandalà, MH Ryu, ... The Lancet 392 (10142), 123-133, 2018 | 1240 | 2018 |
| Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial K Muro, HC Chung, V Shankaran, R Geva, D Catenacci, S Gupta, JP Eder, ... The lancet oncology 17 (6), 717-726, 2016 | 1189 | 2016 |
| Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis AT Shaw, BY Yeap, BJ Solomon, GJ Riely, J Gainor, JA Engelman, ... The lancet oncology 12 (11), 1004-1012, 2011 | 1149 | 2011 |
| Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial SH Noh, SR Park, HK Yang, HC Chung, IJ Chung, SW Kim, HH Kim, ... The lancet oncology 15 (12), 1389-1396, 2014 | 1055 | 2014 |
| Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer K Shitara, YJ Bang, S Iwasa, N Sugimoto, MH Ryu, D Sakai, HC Chung, ... New England Journal of Medicine 382 (25), 2419-2430, 2020 | 1025 | 2020 |
| Predictive and prognostic impact of epidermal growth factor receptor mutation in non–small-cell lung cancer patients treated with gefitinib SW Han, TY Kim, PG Hwang, S Jeong, J Kim, IS Choi, DY Oh, JH Kim, ... Journal of clinical oncology 23 (11), 2493-2501, 2005 | 995 | 2005 |
| Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies TY Kim, DW Kim, JY Chung, SG Shin, SC Kim, DS Heo, NK Kim, YJ Bang Clinical cancer research 10 (11), 3708-3716, 2004 | 986 | 2004 |
| Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 … K Shitara, E Van Cutsem, YJ Bang, C Fuchs, L Wyrwicz, KW Lee, ... JAMA oncology 6 (10), 1571-1580, 2020 | 937 | 2020 |
| HER2-targeted therapies—a role beyond breast cancer DY Oh, YJ Bang Nature reviews Clinical oncology 17 (1), 33-48, 2020 | 885 | 2020 |
| T-cell–inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 … PA Ott, YJ Bang, SA Piha-Paul, ARA Razak, J Bennouna, JC Soria, ... Journal of Clinical Oncology 37 (4), 318-327, 2019 | 816 | 2019 |
